Stay updated on Bispecific Antibody MCLA-158 Clinical Trial

Sign up to get notified when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Bispecific Antibody MCLA-158 Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision updated to v3.5.2 and the previous v3.5.0 revision was removed.
    Difference
    0.0%
    Check dated 2026-04-19T13:48:46.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Added 'Squamous cell carcinoma of the head and neck' to the study's conditions.
    Difference
    0.0%
    Check dated 2026-03-29T00:45:43.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    Revision metadata updated from v3.4.3 to v3.5.0; no changes to the study content.
    Difference
    0.0%
    Check dated 2026-03-21T19:49:51.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. This represents a minor version update with no substantive content updates.
    Difference
    0.0%
    Check dated 2026-03-07T06:17:23.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    Gastric cancer has been added to the Conditions list. The Genetic and Rare Diseases Information Center is now listed as a resource, and the page revision was updated from v3.4.1 to v3.4.2.
    Difference
    0.1%
    Check dated 2026-02-13T13:41:21.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    Merus N.V. was removed and Merus B.V. was added as the sponsor. The page revision updated from v3.4.0 to v3.4.1.
    Difference
    0.2%
    Check dated 2026-02-06T09:11:57.000Z thumbnail image

Stay in the know with updates to Bispecific Antibody MCLA-158 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.